Thalassemia Reports (Mar 2023)

Effect of <i>HFE</i> Gene Mutations on Iron Metabolism of Beta-Thalassemia Carriers

  • María E. Mónaco,
  • Natalia S. Alvarez Asensio,
  • Cecilia Haro,
  • Magdalena M. Terán,
  • Miryam E. Ledesma Achem,
  • Blanca A. Issé,
  • Sandra S. Lazarte

DOI
https://doi.org/10.3390/thalassrep13010010
Journal volume & issue
Vol. 13, no. 1
pp. 113 – 121

Abstract

Read online

The human hemochromatosis protein HFE is encoded by the HFE gene and participates in iron regulation. The aim of this study was to detect the most frequent HFE gene mutations in a control population and in β-thalassemia trait (BTT) carriers, and to study their relationship with iron metabolism. Total blood count, hemoglobin electrophoresis at alkaline pH, HbA2 quantification, iron (Fe), total Fe binding capacity and ferritin were assayed. HFE gene mutations were analyzed by real-time PCR. A total of 119 individuals (69 normal and 50 BTT) were examined. In the control group, 9% (6/69) presented a codon 282 heterozygous mutation (C282Y), and 19% a codon 63 mutation (H63D) (13/69, 11 heterozygotes and 2 homozygotes). In the BTT group, 3 carriers (6%) were heterozygous for C282Y, 14 (28%) for H63D, 1 (2%) for a codon 65 mutation and 1 (2%) was H63D and C282Y double heterozygous. Control group Fe metabolism did not show significant differences (p > 0.05) according to whether or not they carried an HFE gene mutation; while the BTT group with and without HFE mutation showed higher Fe and ferritin than the control group (p HFE gene mutations. It is likely that BTT individuals have other genetic modifiers that affect their iron balance.

Keywords